In the present study, various nanoemulsion formulations of carvone Schiff base of isoniazid (CSB-INH) were
developed by aqueous phase titration method in order to evaluate its anticancer potential. Developed
nanoemulsions of CSB-INH were characterized in terms of thermodynamic stability, self-nanoemulsification
efficiency, droplet size, polydispersity index (PI), zeta potential (ZP), viscosity, refractive index (RI), % transmittance
(% T), surface morphology and in vitro drug release studies. Based on lowest droplet size (19.4 nm), least

In this study, a fast UHPLC-MS/MS method was developed and validated for the determination of a novel potent
carvone Schiff base of isoniazid (CSB-INH) in rat plasma using carbamazepine as an internal standard (IS). After a single-step
protein precipitation by acetonitrile, CSB-INH and IS were separated on an Acquity BEHTM C18 column (50 × 2.1 mm, 1.7 μm)
under an isocratic mobile phase, consisting of acetonitrile: 10mM ammonium acetate (95:5, v/v), at a flow rate of 0.3 mL/

Lead derivatives of 2-cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl)
methylidene]hydrazinecarbothioamides 1–18 were synthesized, characterized and evaluated
in vitro against HER-2 overexpressed breast cancer cell line SKBr-3. All the compounds showed
activity against HER-2 overexpressed SKBr-3 cells with IC50 = 17.44 ± 0.01 μM to 53.29 ±
0.33 μM. (2Z)-2-(3-Hydroxybenzylidene)-N-(3-methoxyphenyl)hydrazinecarbothioamide
(12, IC50 = 17.44 ± 0.01 μM) was found to be most potent compound of this series targeting